Abstract 19277: Statin Therapy Lowers Myocardial Fibrosis Marker sST2 in Patients Living With HIV

• Published in: Circulation (New York, N.Y.) N.Y.), 2016-11, Vol.134 (Suppl_1 Suppl 1), p.A19277-A19277
• Main Authors: Lo, Janet, Defilippi, Christopher, Christenson, Robert, Fitch, Kathleen, Looby, Sara, Kim, Elli, Lu, Michael, Hoffmann, Udo, Grinspoon, Steven
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539

IntroductionWe have recently shown that patients living with HIV have higher soluble ST2 (sST2), galectin-3 and high sensitivity troponin T (hs-cTnT), than non-HIV controls and that hs-cTnT is associated with calcified coronary plaque in patients with HIV. The objective of the current study is to assess effects of statin therapy on these markers of myocardial fibrosis, injury and inflammation in HIV patients.HypothesesAtorvastatin will reduce markers of myocardial fibrosis, injury and inflammation in HIV patients.Methods40 HIV+ men and women participated in a 12-month randomized, double-blind placebo controlled trial of atorvastatin 40mg po qd (starting at 20mg po qd in first 3 months and escalating to 40mg po qd in final 9 months) vs. placebo. Serial sST2, galectin-3, hs-cTnT, sCD14, MCP-1, hs-IL6, hs-CRP and oxidized LDL by ELISA and coronary plaque volume on CT coronary angiography (CCTA) were measured.ResultsAtorvastatin lowered sST2 compared to the placebo group (change in statin group -0.310 [-4.195 to 2.075]ng/mL median[IQR] vs. 1.163 [0.624 to 4.715]ng/mL in the placebo group, p=0.04). The change in sST2 was significantly related to change in monocyte activation markers sCD14 (r=0.63, p